Cargando…
Safety and Tolerability of Adjunctive Eslicarbazepine Acetate in Pediatric Patients (Aged 4-17 Years) With Focal Seizures
OBJECTIVE: To evaluate the safety and tolerability of adjunctive eslicarbazepine acetate (ESL) in pediatric patients (aged 4-17 years) with refractory focal seizures. METHODS: Pooled safety data from patients aged 4-17 years in Study 208 (NCT01527513) and Study 305 (NCT00988156) were analyzed. Both...
Autores principales: | Mintz, Mark, Pina-Garza, Jesus E., Wolf, Steven M., McGoldrick, Patricia E., Józwiak, Sergiusz, Grinnell, Todd, Cantu, David, Costa, Raquel, Moreira, Joana, Li, Yan, Blum, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005936/ https://www.ncbi.nlm.nih.gov/pubmed/31878820 http://dx.doi.org/10.1177/0883073819890997 |
Ejemplares similares
-
Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures
por: Altalib, Hamada, et al.
Publicado: (2022) -
Safety, Tolerability and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy in Patients Aged ≥ 65 Years with Focal Seizures
por: Costa, Raquel, et al.
Publicado: (2018) -
Impact of Early Initiation of Eslicarbazepine Acetate on Economic Outcomes Among Patients with Focal Seizure: Results from Retrospective Database Analyses
por: Mehta, Darshan, et al.
Publicado: (2020) -
Comparative Economic Outcomes in Patients with Focal Seizure Initiating First-Line Eslicarbazepine Acetate Monotherapy versus Generic Antiseizure Drugs
por: Mehta, Darshan, et al.
Publicado: (2021) -
Prediction of efficacy for conversion from adjunctive therapy to monotherapy with eslicarbazepine acetate 800 mg once daily for partial-onset epilepsy
por: Sunkaraneni, Soujanya, et al.
Publicado: (2017)